Photo of Maurizio Fava,  MD

Maurizio Fava, MD

Massachusetts General Hospital

Massachusetts General Hospital
Phone: (617) 724-2513
Fax: (617) 726-2688


mfava@mgh.harvard.edu

Maurizio Fava, MD

Massachusetts General Hospital

EDUCATIONAL TITLES

  • Slater Family Professor of Psychiatry, Psychiatry, Harvard Medical School
  • Psychiatrist-in-Chief, Psychiatry, Massachusetts General Hospital
  • Executive Director, Clinical Trials Network and Institute, Massachusetts General Hospital
  • Director, Division of Clinical Research, MGH Research Institute, Massachusetts General Hospital

DF/HCC PROGRAM AFFILIATION

Research Abstract

Dr. Maurizio Fava is Psychiatrist-in-Chief of the Massachusetts General Hospital (MGH), director, Division of Clinical Research of the MGH Research Institute, executive director of the Clinical Trials Network and Institute, (MGH), associate dean for clinical and translational research and the Slater Family Professor of Psychiatry at Harvard Medical School.

Dr. Fava is a world leader in the field of depression. He has edited eight books and authored or co-authored more than 800 original articles published in medical journals with international circulation, articles which have been cited more than 80,000 times in the literature and with an h index of over 140. Dr. Fava obtained his medical degree from the University of Padova School of Medicine and completed residency training in endocrinology at the same university. He then moved to the United States and completed residency training in psychiatry at MGH. He founded and was director of the hospital’s Depression Clinical and Research Program from 1990 until 2014. Under Dr. Fava’s direction, the Depression Clinical and Research Program became one of the most highly regarded depression programs in the country, a model for academic programs that link, in a bi-directional fashion, clinical and research work. In 2007, he also founded and is now the executive director of the MGH Psychiatry Clinical Trials Network and Institute, the first academic CRO specialized in the coordination of multi-center clinical trials in psychiatry.

Dr. Fava has been successful in obtaining funding as principal or co-principal investigator from both the National Institutes of Health and other sources for a total of more than $120 million. Dr. Fava’s prominence in the field is reflected in his role as the co-principal investigator of STAR*D, the largest research study ever conducted in the area of depression, and of the RAPID Network, the NIMH-funded series of studies of novel, rapidly-acting antidepressant therapies.

Dr. Fava has received several awards during his career and is on the editorial board of five international medical journals. Since 1990, Dr. Fava has also mentored more than 50 trainees who have gone on to become lead investigators in the area of psychiatry. He has developed with Dr. David Schoenfeld a novel design (with over five patents) to address the problem of excessive placebo response in drug trials and to markedly reduce sample size requirements for these trials. In 2009, Dr. Fava received the A. Clifford Barger Excellence in Mentoring Award from Harvard Medical School, and in 2013 the John T. Potts, Jr., MD Faculty Mentoring Award from Massachusetts General Hospital. He is also the former President of the American Society of Clinical Psychopharmacology.

Dr. Fava is a well-known national and international lecturer, having given more than 300 presentations at national and international meetings.

Publications

Powered by Harvard Catalyst
  • Smith SM, Fava M, Jensen MP, Mbowe OB, McDermott MP, Turk DC, Dworkin RH. Size does matter, but it isn't everything: the challenge of modest treatment effects in chronic pain clinical trials. J Pain 2019. PubMed
  • Heo JY, Yi H, Fava M, Mischoulon D, Kim K, Yoon S, Jeon HJ, Lee JE. Agoraphobia and Follicle-Stimulating Hormone Levels between Tamoxifen and Goserelin versus Tamoxifen Alone in Premenopausal Hormone Receptor-Positive Breast Cancer: A 12-Month Prospective Randomized Study. Psychiatry Investig 2017; 14:491-498. PubMed
  • Ostergaard SD, Bech P, Trivedi MH, Wisniewski SR, Rush AJ, Fava M. Brief, unidimensional melancholia rating scales are highly sensitive to the effect of citalopram and may have biological validity: implications for the research domain criteria (RDoC). J Affect Disord 2014; 163:18-24. PubMed
  • Fava M, Ball S, Nelson JC, Sparks J, Konechnik T, Classi P, Dube S, Thase ME. Clinical relevance of fatigue as a residual symptom in major depressive disorder. Depress Anxiety 2014; 31:250-7. PubMed
  • Sarris J, Nierenberg AA, Schweitzer I, Alpert JE, Rosenbaum JF, Iovieno N, Covino J, Fava M, Mischoulon D. Conditional probability of response or nonresponse of placebo compared with antidepressants or St John's Wort in major depressive disorder. J Clin Psychopharmacol 2013; 33:827-30. PubMed
  • Jeon HJ, Peng D, Chua HC, Srisurapanont M, Fava M, Bae JN, Man Chang S, Hong JP. Melancholic features and hostility are associated with suicidality risk in Asian patients with major depressive disorder. J Affect Disord 2013. PubMed
  • Farabaugh A, Alpert J, Wisniewski SR, Otto MW, Fava M, Baer L, Perlis R, Friedman E, Nyer M, Bitran S, Balasubramani GK, Inamori A, Trivedi M, Thase ME. Cognitive therapy for anxious depression in STAR(*) D: what have we learned? J Affect Disord 2012; 142:213-8. PubMed
  • Papakostas GI, Vitolo OV, Ishak WW, Rapaport MH, Zajecka JM, Kinrys G, Mischoulon D, Lipkin SH, Hails KA, Abrams J, Ward SG, Meisner A, Schoenfeld DA, Shelton RC, Winokur A, Okasha MS, Bari MA, Fava M. A 12-week, randomized, double-blind, placebo-controlled, sequential parallel comparison trial of ziprasidone as monotherapy for major depressive disorder. J Clin Psychiatry 2013; 73:1541-7. PubMed
  • Gallagher PJ, Castro V, Fava M, Weilburg JB, Murphy SN, Gainer VS, Churchill SE, Kohane IS, Iosifescu DV, Smoller JW, Perlis RH. Antidepressant response in patients with major depression exposed to NSAIDs: a pharmacovigilance study. Am J Psychiatry 2012; 169:1065-72. PubMed
  • Janes AC, Pizzagalli DA, Richardt S, Frederick Bde B, Holmes AJ, Sousa J, Fava M, Evins AE, Kaufman MJ. Neural substrates of attentional bias for smoking-related cues: an FMRI study. Neuropsychopharmacology 2010; 35:2339-45. PubMed
  • Janes AC, Pizzagalli DA, Richardt S, Frederick BD, Chuzi S, Pachas G, Culhane MA, Holmes AJ, Fava M, Evins AE, Kaufman MJ. Brain Reactivity to Smoking Cues Prior to Smoking Cessation Predicts Ability to Maintain Tobacco Abstinence. Biol Psychiatry 2010; 67:722-9. PubMed
  • Davis LL, Wisniewski SR, Howland RH, Trivedi MH, Husain MM, Fava M, McGrath PJ, Balasubramani GK, Warden D, Rush AJ. Does comorbid substance use disorder impair recovery from major depression with SSRI treatment? An analysis of the STAR*D level one treatment outcomes. Drug Alcohol Depend 2010; 107:161-70. PubMed
  • Kim BW, Kennedy DN, Lehár J, Lee MJ, Blood AJ, Lee S, Perlis RH, Smoller JW, Morris R, Fava M, Breiter HC, . Recurrent, robust and scalable patterns underlie human approach and avoidance. PLoS ONE 2010; 5:e10613. PubMed
  • Janes AC, Frederick B, Richardt S, Burbridge C, Merlo-Pich E, Renshaw PF, Evins AE, Fava M, Kaufman MJ. Brain fMRI reactivity to smoking-related images before and during extended smoking abstinence. Exp Clin Psychopharmacol 2009; 17:365-73. PubMed
  • Kashner TM, Trivedi MH, Wicker A, Fava M, Shores-Wilson K, Wisniewski SR, Rush AJ. Release bias in accessing medical records in clinical trials: a STAR*D report. Int J Methods Psychiatr Res 2009; 18:147-58. PubMed
  • Park ER, Sylvia LG, Streck JM, Luberto CM, Stanton AM, Perez GK, Baim M, Bliss CC, Convery MS, Crute S, Denninger JW, Donelan K, Dossett ML, Fava M, Fredriksson S, Fricchione G, George N, Hall DL, Hart BR, Herman J, Hirschberg A, Holt D, Looby SE, Malloy L, Meek J, Mehta DH, Millstein RA, Mizrach H, Rosa K, Slawsby E, Stupinski AC, Traeger L, Vanderkruik R, Vogeli C, Wilhelm S. Launching a resiliency group program to assist frontline clinicians in meeting the challenges of the COVID-19 pandemic: Results of a hospital-based systems trial. Gen Hosp Psychiatry 2021; 68:111-112. PubMed
Hide